Latest
IgG4-related disease enters real prescribing territory
Inebilizumab IgG4-RD pivotal data, rituximab maintenance protocols, and structured diagnostic pathways are reshaping IgG4-related disease management.
Systemic sclerosis therapy options mature past hematopoietic stem cell transplant
Tocilizumab and nintedanib in SSc-ILD, anifrolumab pivotal data, and emerging mechanism-targeted programs are reshaping systemic sclerosis management.
Giant cell arteritis therapy options widen past corticosteroids
Tocilizumab maturity, secukinumab pivotal data, and emerging mechanism-targeted programs are reshaping giant cell arteritis management.
ANCA-associated vasculitis therapy options mature around avacopan
Avacopan commercial maturity, rituximab maintenance protocols, and emerging mechanism programs are restructuring ANCA-associated vasculitis management.
By signal pillar
Regulatory
1Scientific
20IgG4-related disease enters real prescribing territory
Inebilizumab IgG4-RD pivotal data, rituximab maintenance protocols, and structured diagnostic pathways are reshaping IgG4-related disease management.
Systemic sclerosis therapy options mature past hematopoietic stem cell transplant
Tocilizumab and nintedanib in SSc-ILD, anifrolumab pivotal data, and emerging mechanism-targeted programs are reshaping systemic sclerosis management.
Giant cell arteritis therapy options widen past corticosteroids
Tocilizumab maturity, secukinumab pivotal data, and emerging mechanism-targeted programs are reshaping giant cell arteritis management.
ANCA-associated vasculitis therapy options mature around avacopan
Avacopan commercial maturity, rituximab maintenance protocols, and emerging mechanism programs are restructuring ANCA-associated vasculitis management.
Alopecia areata therapy class competition matures
Baricitinib, ritlecitinib, and deuruxolitinib establish a competitive systemic JAK inhibitor class in severe alopecia areata.
Chimeric autoantibody receptor T cells enter pemphigus vulgaris
Desmoglein 3-targeted CAART cell therapy programs in pemphigus vulgaris are reading out as a precision approach to autoantibody-driven disease.
Lupus nephritis therapy options mature past induction-and-maintenance
Voclosporin and belimumab in lupus nephritis plus emerging mechanism programs are restructuring induction and maintenance therapy.
Hidradenitis suppurativa biologic options widen past TNF
IL-17-class secukinumab and bimekizumab approvals plus emerging novel mechanism programs are restructuring hidradenitis suppurativa management.
Sjogren disease therapy enters real prescribing territory
First positive pivotal readouts in Sjogren disease are establishing a category that has had no specific systemic therapy for decades.
IL-23 dominance in psoriasis settles in
IL-23 inhibitors have become the default systemic option for moderate-to-severe psoriasis, leaving IL-17 and TNF in second-line slots.
Eosinophilic esophagitis as a real prescribing category
Approved biologic therapy for eosinophilic esophagitis has turned a long-overlooked condition into a defined prescribing category.
Atopic dermatitis: a crowded biologic field finds its tiers
Multiple biologic and oral options in atopic dermatitis are sorting into clinical tiers based on response durability and safety.
Long-acting HIV prevention enters routine care
Long-acting injectable HIV prevention is establishing itself alongside daily oral regimens.
JAK inhibitors find their tier
Oral JAK inhibitors are settling into a defined tier across rheumatology, IBD, and dermatology after several years of label and safety recalibration.
IL-class biologics rebalancing immunology
IL-23 and IL-17 agents continue to take share from TNF inhibitors across rheumatology, IBD, and dermatology.
Alopecia areata becomes a real category
Approved JAK inhibitors have turned alopecia areata into an actual prescribing category.
IBD targets move beyond TNF
IL-23, S1P modulators, and oral options are reshaping inflammatory bowel disease therapy choice.
Dermatology's shift from topical to systemic
Atopic dermatitis, psoriasis, and alopecia are moving from topical and steroid mainstays to systemic biologic and small-molecule therapy.
Antimicrobial resistance and the antibiotic gap
Antimicrobial resistance remains the slow-burn infectious-disease story without a sustained commercial answer.
mRNA vaccines beyond the pandemic
mRNA platforms are extending into RSV, influenza, and adult vaccination programs.
Real-world evidence
2TYK2 inhibitor commercial uptake in psoriasis is reshaping the oral-versus-injection conversation
TYK2 inhibitor uptake in psoriasis is establishing the first commercially meaningful oral biologic alternative for moderate-to-severe disease. The route-of-administration conversation is now active in a way it has not been in the IL-23 and IL-17 era.
IBD biologic sequencing patterns reveal the early-line ustekinumab opportunity
Real-world IBD biologic sequencing data shows ustekinumab and adjacent IL-12/23 mechanisms moving earlier in the line of therapy than the historical anti-TNF-first paradigm. The implications for commercial planning across the IBD biologic class are material.